RXi Pharmaceuticals Corp (RXII)

0.67
0.01 2.10
NASDAQ : Health Care
Prev Close 0.68
Open 0.71
Day Low/High 0.66 / 0.71
52 Wk Low/High 1.26 / 6.49
Volume 181.82K
Avg Volume 1.09M
Exchange NASDAQ
Shares Outstanding 22.05M
Market Cap 14.33M
EPS -2.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

RXi Pharmaceuticals Granted Patent In Japan For Lead Clinical Candidate RXI-109

RXi Pharmaceuticals Granted Patent In Japan For Lead Clinical Candidate RXI-109

RXI-109 is a self-delivering RNAi compound (sd-rxRNA) in development to reduce dermal and ocular fibrosis

RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum

RXi Pharmaceuticals To Present At The 5th Annual Cancer BioPartnering & Investment Forum

Focusing on Advances in Immuno-Oncology

RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences

RXi Pharmaceuticals To Present At Leading Investor And Healthcare Conferences

19th Annual BIO CEO & Investor Conference and 2nd Annual Disruptive Growth & Healthcare Conference

RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer

RXi Pharmaceuticals Completes Acquisition Of MirImmune Inc. And Appoints New Chief Business Officer

Acquisition expands RXi's pipeline to include cell-based immunotherapy to treat cancer

RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.

RXi Pharmaceuticals Enters Into Exclusive Option Agreement To Acquire MirImmune Inc.

Acquisition will broaden RXi's pipeline to include immuno-oncology with the use of the Company's proprietary sd-rxRNA® platform

RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum

RXi Pharmaceuticals Corporation Selected to Present at Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences